Silence Therapeutics (SLN) Cash from Investing Activities (2024 - 2026)

Silence Therapeutics has disclosed Cash from Investing Activities across 3 years of filings, most recently posting $10.0 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $10.0 million, up 122.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 138.86% YoY), and the FY2025 annual result was -$48.0 million, down 118.48% from the prior year.
• Cash from Investing Activities came in at $10.0 million for Q1 2026 at Silence Therapeutics, up from -$53.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $66.1 million in Q4 2024 to a low of -$53.3 million in Q4 2025.
• The 3-year median for Cash from Investing Activities is -$1.6 million (2025), against an average of -$6.7 million.
• Peak annual rise in Cash from Investing Activities reached 234.48% in 2025, while the deepest fall reached 3532.56% in 2025.
• Silence Therapeutics' Cash from Investing Activities stood at $66.1 million in 2024, then plunged by 180.66% to -$53.3 million in 2025, then soared by 118.75% to $10.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $10.0 million (Q1 2026), -$53.3 million (Q4 2025), and $51.3 million (Q3 2025), per Business Quant data.